Online inquiry

IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7012MR)

This product GTTS-WQ7012MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CSF3R gene. The antibody can be applied in Neutropenia research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000760.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1441
UniProt ID Q99062
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ7012MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6025MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ11978MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MM-005
GTTS-WQ14437MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ3887MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BCD-100
GTTS-WQ13522MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PRX002
GTTS-WQ5296MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ7614MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ5029MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CA Exendin-4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW